[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363384-105":59,"doc-detail-363384-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeted-microwave-ablation-of-localised-prostate-cancer-violette-trial-a-prospective-multicentre-study","Targeted microwave ablation of localised prostate cancer (VIOLETTE trial): a prospective multicentre study","","Targeted microwave ablation (TMA) was evaluated in men with intermediate-risk, localised prostate cancer within the VIOLETTE prospective, multicentre phase II trial. Oncological outcomes focused on absence of clinically significant prostate cancer (csPCa) within the treated area at 12 months, using organ-based tracking (OBT) fusion guidance for precise needle placement and ablation margins. Seventy-six patients were treated across six centres, with functional safety endpoints and rates of subsequent radical treatment assessed over follow-up.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeted-microwave-ablation-of-localised-prostate-cancer-violette-trial-a-prospective-multicentre-study/363384/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeted-microwave-ablation-of-localised-prostate-cancer-violette-trial-a-prospective-multicentre-study/363384.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the primary endpoint of the VIOLETTE trial?","Question",{"text":112,"@type":113},"The primary endpoint is the absence of clinically significant prostate cancer (csPCa) defined as ISUP Grade Group ≥2 within the treated area at 12 months.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was targeted microwave ablation performed in the study?",{"text":117,"@type":113},"The microwave applicator was placed using organ-based tracking (OBT) Fusion guidance, either transperineally or transrectally, and ablation margins were defined by recalling 3D-positive biopsy locations and MRI lesions.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key safety and functional findings?",{"text":121,"@type":113},"Five serious adverse events occurred in three patients. Sexual and ejaculatory scores decreased significantly, while urinary function remained stable.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363384,1790725182,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","BJU Int 2026; 137: 1032–1039 doi:10.1111/bju.70220  \nOriginal Article  \nTargeted microwave ablation of localised prostate  \ncancer (VIOLETTE trial): a prospective multicentre study  \nNicolas Barry Delongchamps1 , Alexandre Peltier2, Eric Potiron3, Franck Bladou4, Romain Diamand2, Aurel Messas5, Jean-Baptiste Roche6, Grgoire Robert4 , Jean-Louis Hoepffner6, Thierry Piechaud6, Julien Anract1  and Roland van Velthoven2  \n1Department of Urology, H^opital Cochin, APHP, Universit Paris Cit, Paris, France, 2Department of Urology, Jules Bordet Institute, H^opital Universitaire de Bruxelles, Universit Libre de Bruxelles, Bruxelles, Belgium, 3Clinique Urologique Nantes Atlantis, Saint Herblain, 4Department of Urology, CHU de Bordeaux, Universit de Bordeaux, Bordeaux, 5H^opital Amricain de Paris, Neuilly-sur-Seine, and 6Groupe Urologie Saint-Augustin, Bordeaux, France  \nObjective  \nTo assess the oncological outcomes of targeted microwave ablation (TMA) using organ-based tracking (OBT) Fusion􀀁 via KOELIS Trinity􀀁 (KOELIS, Meylan, France) in men with intermediate-risk prostate cancer (PCa): the VIOLETTE trial ([ClinicalTrials.gov](ClinicalTrials.gov) identiﬁer: NCT04582656)  \nPatients and Method  \nIn this prospective phase II, multicentre European study, men with a prostate-speciﬁc antigen (PSA) level \u003C20 ng/mL, a single magnetic resonance imaging (MRI)-visible lesion ≤15 mm, International Society of Urological Pathology (ISUP) Grade Group 2 on MRI-targeted biopsy, and clinical T stage ≤2, were enrolled. The microwave applicator was placed using OBT Fusion guidance, either transperineally or transrectally. The primary endpoint was the absence of clinically signiﬁcant PCa (csPCa), deﬁned as ISUP Grade Group ≥2, within the treated area at 12 months. Secondary endpoints included safety, functional outcomes using validated measures, and the need for subsequent radical treatment.  \nResults  \nA total of 76 patients were treated across six centres with 66 (87%) completing the 12-month follow-up. At 6 months, six patients had csPCa after positive MRI control, including four within the treated area. At 12 months, csPCa was detected in 15 additional patients, including nine in-ﬁeld recurrences, yielding an 81% in-ﬁeld csPCa-free rate. Five serious adverse events in three patients were reported. Sexual (􀀁2.5 points; P \u003C 0.001) and ejaculatory (􀀁1 points; P \u003C 0.001) scores decreased signiﬁcantly, whereas urinary function remained stable. Radical treatment was required in four (5.2%) patients at 12 months.  \nConclusion  \nTargeted microwave ablation using OBT Fusion technology appears to be a safe and effective focal therapy procedure for localised intermediate-risk PCa. The VIOLETTE trial achieved its primary endpoint, with 81% patients free of in-ﬁeldcsPCa at 12 months.  \nKeywords  \nprostate cancer, focal therapy, organ-based tracking, image fusion, transperineal, microwave ablation  \nIntroduction  \nFocal therapy (FT) has gained interest in recent years inpatients with localised clinically signiﬁcant prostate cancer (csPCa) [1] . This potential alternative to whole-gland therapy aims at mitigating adverse impacts on sexual, urinary and  \nbowel function [2], as well as to decrease overtreatment inpatients presenting with earlier stage and smaller size cancers [3] . Various sources of energy have been employed to date to ablate the index tumour, but, according to current guidelines, this treatment strategy remains experimental due to the lack of long-term oncological data [1,4–6] .  \n􀀃 2026 The Author(s) .  \n[wileyonlinelibrary.com](wileyonlinelibrary.com) BJU International published by John Wiley & Sons Ltd on behalf of BJU [International. www.bjui.org](International. www.bjui.org)  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modiﬁcations or adaptations a","cbCaisTocTXIVG8x","https://ap.wps.com/l/cbCaisTocTXIVG8x","pdf",481302,"English","# Objective\n# Patients and Method\n## Study endpoints\n# Results\n## Oncological outcomes\n## Safety and functional outcomes\n# Conclusion\n# Introduction\n## Rationale for focal therapy\n## TMA technique and guidance","[{\"question\":\"What is the primary endpoint of the VIOLETTE trial?\",\"answer\":\"The primary endpoint is the absence of clinically significant prostate cancer (csPCa) defined as ISUP Grade Group ≥2 within the treated area at 12 months.\"},{\"question\":\"How was targeted microwave ablation performed in the study?\",\"answer\":\"The microwave applicator was placed using organ-based tracking (OBT) Fusion guidance, either transperineally or transrectally, and ablation margins were defined by recalling 3D-positive biopsy locations and MRI lesions.\"},{\"question\":\"What were the key safety and functional findings?\",\"answer\":\"Five serious adverse events occurred in three patients. Sexual and ejaculatory scores decreased significantly, while urinary function remained stable.\"}]","Targeted microwave ablation of localised prostate cancer (VIOLETTE trial): a prospective multicentre study | PDF",1790151025,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91cb34fe61d6e18ea4132187540a442c.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4795ab868c64730f5f773609b475026a.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe551ca9da60ffa3a28c763415083c9d.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05342f58447e15883cedd5f13533d71c.webp",980,1287]